Published in J Mol Biol on February 20, 2007
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med (2008) 3.17
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 2.95
Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol (2011) 2.53
Proof of principle for epitope-focused vaccine design. Nature (2014) 2.09
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol (2010) 1.89
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J (2009) 1.48
Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol (2014) 1.48
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol (2011) 1.39
Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol (2010) 1.38
Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis (2010) 1.36
Engineering the variable region of therapeutic IgG antibodies. MAbs (2011) 1.33
In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A (2014) 1.30
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother (2013) 1.24
Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs (2009) 1.17
Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins. Biotechnol J (2009) 1.15
Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol (2013) 1.15
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun (2015) 1.12
Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs (2011) 1.06
Respiratory viruses other than influenza virus: impact and therapeutic advances. Clin Microbiol Rev (2008) 1.05
Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol (2010) 1.03
Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis (2011) 1.03
A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo. J Virol (2007) 1.02
Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol (2012) 0.97
Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res (2014) 0.96
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem (2012) 0.96
Nanohole-based surface plasmon resonance instruments with improved spectral resolution quantify a broad range of antibody-ligand binding kinetics. Anal Chem (2012) 0.96
A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis (2009) 0.96
Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother (2012) 0.95
A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog (2010) 0.92
Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol (2015) 0.90
Emerging paramyxoviruses: molecular mechanisms and antiviral strategies. Expert Rev Mol Med (2011) 0.90
Respiratory viral infections in children with asthma: do they matter and can we prevent them? BMC Pediatr (2012) 0.89
Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus. J Virol (2012) 0.89
A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr (2010) 0.88
7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. MAbs (2012) 0.88
Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev (2016) 0.88
Progress towards recombinant anti-infective antibodies. Recent Pat Antiinfect Drug Discov (2009) 0.88
Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev (2016) 0.86
Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther (2009) 0.85
Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J Clin Invest (2015) 0.85
pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem (2014) 0.85
Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy (2010) 0.84
Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus. Virol J (2007) 0.84
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother (2015) 0.84
Antibody engineering for increased potency, breadth and half-life. Curr Opin HIV AIDS (2015) 0.83
Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery. Methods Mol Biol (2009) 0.82
Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. Virology (2014) 0.82
Genetically delivered antibody protects against West Nile virus. Antiviral Res (2007) 0.81
Managing the morbidity associated with respiratory viral infections in children with congenital heart disease. Int J Pediatr (2012) 0.81
The influence of antibody fragment format on phage display based affinity maturation of IgG. MAbs (2014) 0.80
Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses. Expert Rev Vaccines (2015) 0.80
Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge. Gene Ther (2010) 0.80
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Proc Natl Acad Sci U S A (2016) 0.79
Motavizumab. MAbs (2009) 0.79
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model. Antimicrob Agents Chemother (2010) 0.79
Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol (2016) 0.78
Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs (2016) 0.78
Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350. Open Virol J (2012) 0.78
In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation. MAbs (2014) 0.78
A single amino acid in the F2 subunit of respiratory syncytial virus fusion protein alters growth and fusogenicity. J Gen Virol (2013) 0.78
Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease. Antiviral Res (2014) 0.78
Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus. PLoS One (2016) 0.77
Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Sci Rep (2016) 0.77
Protein Crystallography in Vaccine Research and Development. Int J Mol Sci (2015) 0.77
The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. Clin Dev Immunol (2013) 0.77
RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function. J Gen Virol (2013) 0.77
Burden of respiratory syncytial virus infection in young children. World J Clin Pediatr (2012) 0.77
The infectious march: the complex interaction between microbes and the immune system in asthma. Immunol Allergy Clin North Am (2010) 0.77
Role of infections in the induction and development of asthma: genetic and inflammatory drivers. Expert Rev Clin Immunol (2009) 0.76
Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin. Nanomedicine (2015) 0.75
Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine (2016) 0.75
Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun (2017) 0.75
In silico approach towards designing virtual oligopeptides for HRSV. ScientificWorldJournal (2014) 0.75
Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis. J R Soc Med (2009) 0.75
Characterization of Pre-F-GCN4t, a modified human respiratory syncytial virus fusion protein stabilized in a non-cleaved pre-fusion conformation. J Virol (2017) 0.75
Nonspecificity in a nonimmune human scFv repertoire. MAbs (2017) 0.75
A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein. Nat Microbiol (2017) 0.75
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. MAbs (2017) 0.75
Protection of calves by a prefusion-stabilized bovine RSV F vaccine. NPJ Vaccines (2017) 0.75
Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother (2017) 0.75
Antibody-induced internalization of the human respiratory syncytial virus fusion protein. J Virol (2017) 0.75
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 4.15
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med (2010) 2.36
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum (2009) 2.14
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
Type I interferon: potential therapeutic target for psoriasis? PLoS One (2008) 2.08
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum (2013) 2.06
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood (2011) 1.95
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis (2011) 1.91
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol (2010) 1.86
Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis (2006) 1.84
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol (2005) 1.80
YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol (2008) 1.78
Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum (2007) 1.72
Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol (2010) 1.58
Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol (2003) 1.57
Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med (2011) 1.53
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res (2007) 1.48
Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog (2013) 1.47
Differential expression of chitinases identify subsets of murine airway epithelial cells in allergic inflammation. Am J Physiol Lung Cell Mol Physiol (2006) 1.44
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol (2010) 1.41
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis (2011) 1.37
Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe (2007) 1.37
Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother (2005) 1.32
Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog (2012) 1.31
Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother (2007) 1.30
Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe (2009) 1.27
Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol (2006) 1.25
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res (2008) 1.25
Capturing a flavivirus pre-fusion intermediate. PLoS Pathog (2009) 1.24
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother (2013) 1.24
Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci U S A (2010) 1.23
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus. Hum Genomics Proteomics (2009) 1.22
Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog (2013) 1.20
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes (2013) 1.19
Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol (2009) 1.19
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res (2007) 1.15
The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol (2009) 1.14
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J Clin Invest (2015) 1.13
Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis (2008) 1.13
Differential EphA2 epitope display on normal versus malignant cells. Cancer Res (2003) 1.12
Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology (2007) 1.10
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med (2011) 1.10
Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis (2004) 1.10
Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein. J Immunol (2009) 1.09
Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol (2006) 1.09
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther (2010) 1.09
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother (2009) 1.08
Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther (2006) 1.08
IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. Immunol Lett (2009) 1.08
A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol (2010) 1.08
CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood (2006) 1.07
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis (2013) 1.06
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res (2012) 1.06
Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis (2011) 1.03
West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. J Neurovirol (2008) 1.01
PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin Cancer Res (2004) 1.00
Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant (2011) 0.99
Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. J Infect Dis (2011) 0.99
Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology (2009) 0.97
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res (2011) 0.96
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia (2009) 0.95
Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. MAbs (2013) 0.93
Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob Agents Chemother (2010) 0.92
Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum (2010) 0.92
Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J Virol (2013) 0.90
Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice. Respir Res (2010) 0.89
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs (2012) 0.89
Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization. Adv Enzyme Regul (2007) 0.87
Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus. J Gen Virol (2008) 0.87
Antibody humanization by framework shuffling. Methods (2005) 0.87
Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorg Med Chem Lett (2004) 0.83
Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection. J Infect Dis (2012) 0.81
Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J Med Chem (2003) 0.81